Floatz logo

PEGFILGRASTIM

Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Northwestern University
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3BB

View all 22 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →